Login to Your Account

Pozen Slides on FDA Endpoint Review, Generic Treximet Filing

By Jennifer Boggs

Monday, October 20, 2008
Shares of Pozen Inc. fell 27.8 percent on a double dose of potentially troublesome news involving a delay in one of its investigational NSAID programs and a generic challenge to its recently approved migraine drug Treximet. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription